We are sharing this research opportunity on behalf of Evidera, an independent healthcare research company, on a study examining side effects associated with steroid medications. Evidera’s team is hoping to gain more insight into these side effects and how they impact one’s quality of life by conducting one-on-one interviews with individuals with CIDP, who have…
LaGrippe Research, a market research firm specializing in healthcare, is inviting individuals diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), as well as family members who help support/care for a loved one diagnosed with CIDP, to participate in their research study. This will be an in-person usability study, and those who qualify will be invited to…
Submitted by Dr. Gareth Parry, Global Medical Advisory Board Member and GBS Support Group NZ Trust An online activity-focused coaching programme helps reduce fatigue in people after Guillain-Barré Syndrome 60-80% of people with Guillain-Barré Syndrome (GBS) report persistent fatigue which significantly limits everyday functioning despite good recovery of strength. Dr Suzie Mudge who is a…
Development of a major histocompatibility complex class II conditional knockout mouse to study cell-specific and time-dependent adaptive immune responses in peripheral nerves Published by: Eroboghene E. Ubogu MD, Jeremy A. Conner BS, Yimin Wang PhD, Dinesh Yadav PhD, Thomas L. Saunders PhD Read the research article here: https://onlinelibrary.wiley.com/doi/10.1002/mus.28193
Inspiring the Next Generation of Research at the GBS|CIDP Foundation International Patient Symposium
As part of the 2023 International Patient Symposium, the Foundation was thrilled to welcome seven young medical professionals – ranging from those in their residency to those finishing their Ph.D. – to join the conference and learn from our Global Medical Advisory Board and from the patient community. These young professionals attended sessions, facilitated Q&A’s,…
We Invite You to Participate! As valued members of our medical community, we would like to inform you and your colleagues in training, residents, and fellows of a special opportunity to participate in the 2023 GBS|CIDP Foundation Patient Symposium, October 5-7 in Alexandria, VA. Poster Request Drs. Jeffrey Allen and Bart Jacobs, as Chair and…
A one-year Research Update from the 2022 Benson Fellowship Awardee, Elba Pascual-Goñi MD, PhD. Our 2022 Benson Fellow, Dr. Pascual-Goñi, carries out patient care and translational research tasks in the field of inflammatory neuropathies in the Neuromuscular Diseases Unit of the Hospital de la Santa Creu i Sant Pau (Barcelona). She is responsible for…
Children with rapid-onset paralysis: is it GBS? by Patricia Blomkwist An interesting article* was published in the “European Journal of Neurology” about a study in children. Prof. Bart Jacobs (Erasmus Medical Center, Rotterdam, The Netherlands) was one of the authors. He wondered why, contrary to expectations, some children diagnosed with GBS did not recover well….
Propionate Exerts Neuroprotective and Neuroregenerative Effects in the Peripheral Nervous System A recent study from Ruhr-University Bochum, Germany, was able to demonstrate that the short-chain fatty acid, propionate, has a protective and regenerative effect on the peripheral nervous system in cell culture and in animal experiments. Dr. Thomas Grüter who headed the cell culture and…
Announcing 2022 Benson Fellowship Awardee, Elba Pascual Goñi MD, PhD The Benson Fellowship is a three-year fellowship that provides an opportunity for scientists to engage in peripheral nerve of study. The Fellowship provides funds of up to $150,000 for three years, but only one Benson fellowship is awarded every three year period. We are pleased…
The IGOS-1000 cohort has now been tested for the main preceding infections and is currently tested for antibodies extensively. We have also recently finalized a study in IGOS on the association between GBS and SARS-CoV-2 during the first 3 months of the pandemic. In my view this study shows the importance of having an ongoing…
A UK based epidemiological study, linked below, has found no causal association between COVID-19 infection and Guillain-Barré syndrome. This means that GBS developing at the same time or close to that of COVID-19 is most likely coincidental.
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS Principal Investigators: Luana Benedetti, MD, PhD and Lucilla Nobbio, PhD, University of Genova, ITALY CIDP and GBS are immune-mediated neuropathies characterized by strong heterogeneity in terms of clinical manifestations, prognosis and response to treatment. They are treatable diseases and early…
On September 29, 2020, the GBS|CIDP Foundation International organized a patient-led listening session on Guillain-Barre Syndrome (GBS). More than 30 members of various branches within the FDA logged on to the virtual meeting to hear about patients’ experiences with GBS. The FDA’s role was to listen and learn about what life is like during and…
In 2016 The GBS|CIDP Foundation awarded a research grant to Eduardo Nobile-Orazio, MD, PhD, FAAN, Professor of Neurology Neuromuscular and Neuroimmunology Service at Milan University. Dr. Nobile-Orazio’s 2016 study titled: An Italian Multicenter Network for the diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and of its variants, contributed to the 2019 article: Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database., published by the EAN (European Academy of Neurology). Update: GBS|CIDP Foundation Research 2016 Grant Recipient, Dr. Eduardo Nobil-Orazio, published in Journal of Neurology, Journal of Neuroimmunology, and Wiley Online Library, and EAN.